Clinical Trials Directory

Trials / Completed

CompletedNCT02759289

Arsenic, Disordered Glucose Homeostasis and Atherosclerosis

Arsenic Exposure, Disordered Glucose Homeostasis and Atherosclerosis Protocol

Status
Completed
Phase
Study type
Observational
Enrollment
279 (actual)
Sponsor
NYU Langone Health · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Investigators will recruit 250 subjects; Group A will consist of 100 prediabetic patients with an A1c of 5.7%-6.4%. Group B will consist of 100 patients with uncontrolled T2D defined as either a) an A1c of 6.5%-7.9% without diabetes medications or b) an A1c ≥ 8.0% with or without diabetes medications. Group C will include 50 participants without T2D or known cardiovascular disease to serve as control comparisons.

Detailed description

Patients with prediabetes have an elevated risk of cardiovascular disease (CVD). Cardiovascular disease (CVD) is also the leading cause of morbidity and mortality in patients with Type 2 Diabetes. There remains an unmet clinical need to identify modifiable risk factors for CVD in patients with disordered glucose homeostasis, including prediabetes and T2D. Exposure to inorganic arsenic and other environmental toxicants may be novel targets for CVD risk reduction for these patients. However, there have been no clinical studies of environmental exposures on vascular function and thrombotic risk among patients with prediabetes and growing understanding of environmental exposures as modifiable risk factors for CVD, and can have an impact by: (1) describing the role of environmental exposures for patients with or at risk for T2D; (2) identifying T2D patients at higher risk for the adverse biological effects of environmental exposures; and (3) informing health policies and treatment pathways to reduce the risk of these exposures. Investigators will evaluate the association between inorganic arsenic exposure and measures of vascular function, estimate the association between inorganic arsenic exposure and measures of thrombotic risk and will explore the independent association between environmental exposures other than inorganic arsenic and measures of vascular function and thrombotic risk.

Conditions

Timeline

Start date
2015-11-01
Primary completion
2020-09-15
Completion
2020-09-15
First posted
2016-05-03
Last updated
2020-11-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02759289. Inclusion in this directory is not an endorsement.